BRIACELL THERAPEUTICS CORP C/WTS 26/02/2026(TO PUR COM) | 10-K: FY2025 Revenue: USD 0

LB filings
2025.10.16 10:07
portai
I'm PortAI, I can summarize articles.

Revenue: As of FY2025, the actual value is USD 0.

EPS: As of FY2025, the actual value is USD -62.19.

EBIT: As of FY2025, the actual value is USD -27.34 M.

Segment Revenue

  • Bria-IMT™ Pivotal Phase 3 Study: $13,511,235 in 2025 compared to $11,594,463 in 2024.
  • Bria-IMT™ Phase 1/2a: $1,013,828 in 2025 compared to $4,239,415 in 2024.
  • Bria-OTS™ Phase 1/2a: $428,233 in 2025 compared to $nil in 2024.

Operational Metrics

  • Net Loss: -$26,311,867 in 2025 compared to -$4,791,466 in 2024.
  • Operating Costs: $27,204,803 in 2025 compared to $33,330,076 in 2024.

Cash Flow

  • Operating Cash Flow: -$28,170,520 in 2025 compared to -$24,126,128 in 2024.

Unique Metrics

  • Share of Loss on Equity Investment: -$224,212 in 2025 compared to -$106,510 in 2024.
  • Change in Fair Value of Warrant Liability: $758,364 in 2025 compared to $28,242,472 in 2024.

Outlook / Guidance

  • The Company anticipates reporting top line data from its ongoing pivotal Phase 3 clinical study as early as H1-2026. The study is expected to enroll 177 patients in the Bria-IMT™ combination therapy arm and 177 patients in the treatment of physician’s choice arm. The study will have an interim evaluation for efficacy which could result in early completion of the study.
Source: LB filings The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.